Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
Expert Opin Biol Ther. 2023 Jul-Dec;23(12):1211-1217. doi: 10.1080/14712598.2023.2296569. Epub 2023 Dec 28.
On 31 July 2023, the United States Department of Health and Human Services announced the formation of the Office of Long COVID Research and Practice and the United States National Institutes of Health (NIH) opened enrollment for the therapeutic arm of the RECOVER initiative, a prospective, randomized study to evaluate new treatment options for long coronavirus disease 2019 (long COVID).
One of the first drugs to be studied in this nationwide initiative is intravenous immunoglobulin (IVIG), which will be a treatment option for subjects enrolled in RECOVER-AUTO, a randomized trial to investigate therapeutic strategies for autonomic dysfunction related to long COVID.
IVIG is a mixture of human antibodies (human immunoglobulin) that has been widely used to treat a variety of diseases, including immune thrombocytopenia purpura, Kawasaki disease, chronic inflammatory demyelinating polyneuropathy, and certain infections such as influenza, human immunodeficiency virus, and measles. However, the role of IVIG in the treatment of post-COVID-19 conditions is uncertain. This manuscript examines what is known about IVIG in the treatment of long COVID and explores how this therapeutic agent may be used in the future to address this condition.
2023 年 7 月 31 日，美国卫生与公众服务部宣布成立长期 COVID 研究和实践办公室，美国国立卫生研究院（NIH）开始招募 RECOVER 计划的治疗部分，这是一项前瞻性、随机研究，旨在评估针对 2019 年冠状病毒病（COVID-19）长期后遗症的新治疗选择。
在这项全国性倡议中，首批研究的药物之一是静脉注射免疫球蛋白（IVIG），这将是 RECOVER-AUTO 试验的一种治疗选择，该试验旨在研究与长期 COVID 相关的自主神经功能障碍的治疗策略。
IVIG 是一种混合了人体抗体（人免疫球蛋白）的药物，已广泛用于治疗多种疾病，包括免疫性血小板减少性紫癜、川崎病、慢性炎症性脱髓鞘性多发性神经病以及某些感染，如流感、人类免疫缺陷病毒和麻疹。然而，IVIG 在治疗 COVID-19 后病症中的作用尚不确定。本文探讨了 IVIG 在治疗长期 COVID 方面的作用，并探讨了这种治疗药物未来如何用于解决这一病症。
